Abstract | Background:
Primary orthostatic tremor (POT) remains a therapeutic conundrum. Various medication classes have been tried, yielding modest results at best. Case Report: A 62-year-old female with a 13-year history of POT, refractory to clonazepam up to 20 mg/day, was treated with perampanel 1-2 mg/day. She reported 90% subjective symptomatic improvement. Discussion: This case highlights the potential for use of perampanel, a novel AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist for the treatment of POT. There has been one prior report citing its use for POT with complete resolution of symptoms. We encourage further studies to highlight its efficacy for POT.
|
Authors | Anant Wadhwa, Sara M Schaefer |
Journal | Tremor and other hyperkinetic movements (New York, N.Y.)
(Tremor Other Hyperkinet Mov (N Y))
Vol. 9
( 2019)
ISSN: 2160-8288 [Electronic] England |
PMID | 31413897
(Publication Type: Case Reports)
|
Chemical References |
- Anticonvulsants
- Nitriles
- Pyridones
- Receptors, AMPA
- Clonazepam
- alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
- perampanel
|
Topics |
- Anticonvulsants
(therapeutic use)
- Clonazepam
(therapeutic use)
- Dizziness
(diagnosis, drug therapy)
- Female
- Humans
- Middle Aged
- Nitriles
- Pyridones
(therapeutic use)
- Receptors, AMPA
(drug effects)
- Treatment Outcome
- Tremor
(diagnosis, drug therapy)
- alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
(therapeutic use)
|